Sanofi, AZ's blockbuster hopeful RSV med nears first approval as showdown with Pfizer, GSK looms

Racing against Pfizer and GSK in respiratory syncytial virus (RSV), AstraZeneca and Sanofi have cleared a key hurdle on the path to approval for their potential blockbuster nirsevimab. Still, the single-dose antibody—which will sport the brand name Beyfortus—has much to prove amid the prospect of oncoming competition.